FACULTY
Treat Early/Treat Aggressively: Examining a New Paradigm in Diabetes Management
Including proceedings from a roundtable held in Chicago, Illinois
Activity Date: October 2009  — Activity Info: Volume 6, (6)
Goals & Objectives | Faculty | Complete Pre-Test Activity | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired)

 

Full Disclosure Policy Affecting CPE Activities:
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

COURSE DIRECTOR

L. Brian Cross, PharmD, CDE
Associate Professor
University of Tennessee Health Science Center
Colleges of Pharmacy and Medicine
Memphis, Tennessee
Pharmacotherapy Specialist
Holston Medical Group
Department of Integrated Health Management Services
Kingsport, Tennessee
• Dr Cross reports serving as a consultant and receiving speaker fees from Amylin Pharmaceuticals and Eli Lilly and Company.


PARTICIPATING FACULTY

Carlos A. Alvarez, PharmD, MSc, BCPS
Assistant Professor of Pharmacy Practice
Texas Tech University Health Sciences
Center School of Pharmacy
Dallas, Texas
• Dr Alvarez reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Susan Cornell, PharmD, CDE, FAPhA, FAADE
Clinical Pharmacist and Diabetes Educator
Access DuPage Community Clinic
Assistant Director of Experiential Education
Assistant Professor of Pharmacy Practice
Midwestern University, Chicago College
of Pharmacy
Downers Grove, Illinois
• Dr Cornell reports receiving non-CME speaker fees from the Johnson and Johnson Diabetes Institute; and receiving speaker fees from Abbot, Merck & Co, Inc, Novo Nordisk, and Takeda Pharmaceutical Company Limited.

Tom A. Elasy, MD, MPH
Medical Director
Vanderbilt Eskind Diabetes Center
Editor-in-Chief, Clinical Diabetes
Nashville, Tennessee
• Dr Elasy reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Michael P. Kane, PharmD, FCCP, BCPS
Professor, Department of Pharmacy Practice
Albany College of Pharmacy and Health
Sciences
Clinical Pharmacy Specialist
The Endocrine Group
Albany, New York
• Dr Kane reports receiving research grants from Abbott Diabetes Care.

Sheldon J. Rich, RPh, PhD
President, SJR Associates, LLC
Palm Beach Gardens, FL
Clinical Assistant Professor, University
of Michigan
Ann Arbor, MI
Adjunct Assistant Professor, Wayne State
University
Detroit, MI
• Dr Rich reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Philip T. Rodgers, PharmD, BCPS, CDE, CPP, FCCP
Director of Pharmacy Education
Duke Area Health Education Center
Clinical Associate Professor
University of North Carolina Eshelman
School of Pharmacy
Ambulatory Care Residency
Director and Clinical Pharmacist
Duke University Medical Center
Durham, North Carolina
• Dr Rodgers reports having no significant financial or advisory relationships with corporate organizations related to this activity.

John R. White, Jr, PharmD, PA-C
Professor
Department of Pharmacotherapy,
College of Pharmacy
Washington State University
Spokane, Washington
• Dr White reports receiving consulting fees from Axio Pharmaceutical Company and Sidley Austin, LLP; and receiving honoraria from American Association of Rehabilitation Nurses, American Diabetes Association, Haymarket Medical Education, and Landmark Medical Education.

Notice: In accordance with ACPE Criteria for Quality, the audience is advised that this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investiagional use of therapeutic agent or biomedical device.

University of Tennessee Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. University of Tennessee Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

     
Home | Contact Us | View Account | Need Help?